What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?
Vancouver Island Centre, BC Cancer Agency, University of British Columbia, British Columbia, Canada
Aug 2007 (Vol. 14, Issue 4, Pages( 3621 - 3627)
PMID: 17784982